TORBUGESIC- butorphanol tartrate solution

Land: USA

Språk: engelska

Källa: NLM (National Library of Medicine)

Aktiva substanser:

BUTORPHANOL TARTRATE (UNII: 2L7I72RUHN) (BUTORPHANOL - UNII:QV897JC36D)

Tillgänglig från:

Zoetis Inc.

INN (International namn):

BUTORPHANOL TARTRATE

Sammansättning:

BUTORPHANOL TARTRATE 10 mg in 1 mL

Administreringssätt:

INTRAVENOUS

Receptbelagda typ:

PRESCRIPTION

Terapeutiska indikationer:

TORBUGESIC (butorphanol tartrate injection) is indicated for the relief of pain associated with colic in adult horses and yearlings. Clinical studies in the horse have shown that TORBUGESIC alleviates abdominal pain associated with torsion, impaction, intussusception, spasmodic and tympanic colic and postpartum pain.

Produktsammanfattning:

50 mL vials TORBUGESIC (butorphanol tartrate injection) Veterinary Injection, 10 mg base activity per mL. 10 mL vials TORBUGESIC (butorphanol tartrate injection) Veterinary Injection, 10 mg base activity per mL. Store at controlled room temperature 20°-25°C (68°-77°F) with excursions between 15°-30°C (59°-86°F).

Bemyndigande status:

New Animal Drug Application

Produktens egenskaper

TORBUGESIC- BUTORPHANOL TARTRATE SOLUTION
ZOETIS INC.
----------
TORBUGES IC
(BUTORPHANOL TARTRATE INJECTION)
Torbugesic®
(butorphanol tartrate injection)
CAUTION
Federal (USA) law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION
TORBUGESIC (butorphanol tartrate injection) is a totally synthetic,
centrally acting, narcotic agonist-
antagonist analgesic with potent antitussive activity. It is a member
of the phenanthrene series. The
chemical name is Morphinan-3, 14-diol, 17-(cyclobutylmethyl)-, (-)-,
(S- (R*, R*))-2,3-
dihydroxybutanedioate (1:1) (salt). It is a white, crystalline, water
soluble substance having a molecular
weight of 477.55; its molecular formula is C21H29NO2•C4H6O6.
CHEMICAL STRUCTURE
Each mL of TORBUGESIC contains 10 mg butorphanol base (as butorphanol
tartrate), 3.3 mg citric
acid, USP, 6.4 mg sodium citrate, 4.7 mg sodium chloride, and 0.1 mg
benzethonium chloride, q.s. with
water for injection.
CLINICAL PHARMACOLOGY
COMPARATIVE PHARMACOLOGY
In animals, butorphanol has been demonstrated to be 4 to 30 times more
potent than morphine and
pentazocine (Talwin -V) respectively.
In humans, butorphanol has been shown to have 5 to 7 times the
analgesic activity of morphine and 20
times that of pentazocine.
®
®
1
2,3
Butorphanol has 15 to 20 times the oral antitussive activity of
codeine or dextromethorphan in dogs and
guinea pigs.
As an antagonist, butorphanol is approximately equivalent to
nalorphine and 30 times more potent than
pentazocine.
Cardiopulmonary depressant effects are minimal after treatment with
butorphanol as demonstrated in
dogs , humans
and horses.
Unlike classical narcotic agonist analgesics which are associated with
decreases in blood pressure,
reduction in heart rate and concomitant release of histamine,
butorphanol does not cause histamine
release.
Furthermore, the cardiopulmonary effects of butorphanol are not
distinctly dosage-related but rather
reach a ceiling effect beyond which further
dosage increases result in relatively lesser eff